Pharmicell (005690) — Cash Flow-to-Debt Ratio
Pharmicell (005690) has a Cash Flow-to-Debt Ratio of 0.45x as of September 2025, meaning its operating cash flow of ₩8.78 Billion could theoretically repay 0% of its total liabilities (₩19.60 Billion) in one year. See cash generation quality of Pharmicell to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pharmicell Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Pharmicell across 13 annual periods. Also explore Pharmicell (005690) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Pharmicell (2010–2024)
Year-by-year debt coverage analysis for Pharmicell. For market capitalisation and broader financial context, see Pharmicell stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.27x | ₩3.50 Billion | ₩12.83 Billion | ▼ -72.0% |
| 2023 | 0.97x | ₩11.81 Billion | ₩12.12 Billion | ▲ +306.2% |
| 2022 | 0.24x | ₩7.91 Billion | ₩32.98 Billion | ▲ +240.0% |
| 2021 | -0.17x | ₩-5.22 Billion | ₩30.46 Billion | ▼ -124.1% |
| 2020 | 0.71x | ₩8.98 Billion | ₩12.64 Billion | ▲ +11152.1% |
| 2019 | -0.01x | ₩-75.50 Million | ₩11.75 Billion | ▼ -102.2% |
| 2018 | 0.29x | ₩3.40 Billion | ₩11.63 Billion | ▲ +213.2% |
| 2017 | -0.26x | ₩-2.01 Billion | ₩7.76 Billion | ▼ -292.5% |
| 2016 | 0.13x | ₩988.97 Million | ₩7.36 Billion | ▲ +184.7% |
| 2013 | -0.16x | ₩-2.69 Billion | ₩16.95 Billion | ▲ +53.4% |
| 2012 | -0.34x | ₩-11.87 Billion | ₩34.84 Billion | ▲ +61.4% |
| 2011 | -0.88x | ₩-16.17 Billion | ₩18.33 Billion | ▼ -107.9% |
| 2010 | -0.42x | ₩-8.41 Billion | ₩19.84 Billion | — |